PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
5/24/2013 9:55:34 AM
More...
|
PuraMed BioScience Release: LipiGesic® M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications
5/22/2013 9:22:53 AM
More...
|
PuraMed BioScience Launches Its Business-to-Business Migraine First Aid Kit™ to Promote Workplace Health and Wellness
5/16/2013 9:51:31 AM
More...
|
PuraMed BioScience Expands International Distribution With Order From Colombia, South America
5/13/2013 10:08:35 AM
More...
|
PuraMed BioScience Announces Manufacturing and Packaging Vendors for LipiGesic® M, Its Highly Effective, Non-Prescription Migraine Pain Reliever
4/19/2013 8:52:26 AM
More...
|
PuraMed BioScience Release: Reanalysis of Clinical Trial Data Confirms LipiGesic® M has Robust Efficacy for Treatment of Migraine Headache and Associated Symptoms
3/6/2013 9:07:02 AM
More...
|
PuraMed BioScience, Manufacturers of LipiGesic® M, Engaged FOCUS LLC, an Investment Banking Firm, to Explore Strategic Alternatives
2/27/2013 9:21:26 AM
More...
|
PuraMed BioScience Receives Patent Allowance on Over-the-Counter Migraine Pain Reliever, LipiGesic®M
1/15/2013 9:29:25 AM
More...
|
PuraMed BioScience Release: LipiGesic™ is Recognized by Headache Experts as an Excellent First-Line Therapy for Acute Migraine Treatment
11/13/2012 9:51:07 AM
More...
|
PuraMed BioScience Retains Richard J. Berman as Investment Consultant
11/5/2012 12:48:30 PM
More...
|
|